Longidase lyophilisate for injection 3000IU vial. No. 5
Longidaza® is applied subcutaneously (near the site of the lesion or under scar tissue) or intramuscularly at a dose of 3000 IU in a course of 5 to 25 injections (depending on the disease) with an interval between injections of 3 to 10 days. Methods of application are selected by the doctor depending on the diagnosis, severity of the disease, clinical course, and age of the patient. If necessary, a repeat course is recommended after 2-3 months. In the case of treatment of diseases accompanied by a severe chronic productive process in the connective tissue, after the standard course, long-term maintenance therapy with Longidaza® 3000 IU is recommended with breaks between injections of 10-14 days. To increase the bioavailability of drugs and diagnostic agents, a dose of 1500 IU is recommended with a preliminary 10-15 minute intramuscular or subcutaneous injection into the same place as the main drug.
Breeding
- The contents of the ampoule or bottle of Longidaza® 3000 IU are dissolved in 1-2 ml of procaine solution (0.25% or 0.5%). In case of intolerance to procaine, the drug is dissolved in the same volume of 0.9% sodium chloride solution for injection or water for injection.
- When used to increase bioavailability, the contents of an ampoule or vial of Longidaza® 3000 IU are dissolved in 2 ml, and with a dose of 1500 IU - in 1 ml of 0.9% sodium chloride solution for injection. The solvent must be introduced into the vial or ampoule slowly, wait for 2-3 minutes, and carefully mix without shaking so as not to foam the protein. The prepared solution for parenteral administration cannot be stored. Do not administer IV!
Recommended prevention and treatment regimens For the prevention of adhesive disease and severe scarring after surgical interventions on the abdominal and pelvic organs IM at a dose of 3000 IU 1 time every 3 days for a course of 5 injections. If necessary, the use of the drug can be continued with a general course of up to 10 injections when administered once every 5 days.
For the treatment in gynecology: adhesions in the pelvis for inflammatory diseases of the internal genital organs - 3000 IU intramuscularly once every 3-5 days for a course of 10-15 injections; tubal-peritoneal infertility - 3000 IU intramuscularly for a total course of up to 15 injections: the first 5 injections once every 3 days, then - once every 5 days.
in urology: chronic prostatitis - 3000 IU intramuscularly once every 5 days, course of 10-15 injections; interstitial cystitis - 3000 IU intramuscularly once every 5 days, for a course of up to 10 injections. in surgery: - adhesive disease after surgical interventions on the abdominal organs - intramuscularly at a dose of 3000 IU once every 3-5 days for a course of 10 to 15 injections;
long-term non-healing wounds - IM at a dose of 3000 IU once every 5 days for a course of 5-10 injections. in dermatovenereology, cosmetology: limited scleroderma - 3000-4500 IM intramuscularly once every 3-5 days for a course of up to 20 injections. The dose and course are selected individually depending on the clinical course, stage, location of the disease and the individual characteristics of the patient; keloid, hypertrophic and developing scars after pyoderma, burns, operations, injuries - intra-scar or subcutaneous injection near the site of the lesion, administration 1 time every 3 days, for a course of up to 15 injections at a dosage of 3000-4500 IU. The volume of dilution of Longidaza® is selected by the doctor depending on the number of injection points. If necessary, the course can be continued according to the scheme once every 5 days up to 25 injections. Depending on the area of skin damage and the age of scar formation, alternating subcutaneous and intramuscular administration is possible once every 5 days at a dose of 3000 IU, for a course of up to 20 injections.
in pulmonology and phthisiology: pneumosclerosis - 3000 IU intramuscularly once every 5 days for a course of 10 injections; fibrosing alveolitis - intramuscularly at a dose of 3000 IU once every 5 days for a course of 15 injections, then maintenance therapy once every 10 days for a total course of up to 25 injections; tuberculosis - intramuscularly at a dose of 3000 IU once every 5 days for a course of up to 25 injections; Depending on the clinical picture and severity of the disease, long-term therapy is possible (from 6 months to 1 year at a dose of 3000 IU once every 10 days).
in orthopedics: joint contractures - subcutaneously near the site of the lesion at a dose of 3000 IU once every 3 days for a course of 5 to 15 injections; arthrosis, ankylosing spondylitis - subcutaneous injection near the site of the lesion in a dose of 3000 IU once every 3 days for a course of up to 15 injections, if necessary, treatment can be continued with injections once every 5 days. The duration of maintenance therapy is selected by the doctor depending on the severity of the disease; hematomas - subcutaneously near the site of the lesion at a dose of 3000 IU once every 3 days for a course of up to 5 injections. To increase bioavailability: when administered subcutaneously or intramuscularly with diagnostic or medicinal drugs (antibiotics, chemotherapy drugs, anesthetics and others), Longidaza® is administered 10-15 minutes beforehand at a dose of 1500 IU in the same way and at the same place, as the main drug.
Longidaza lyophilisate for the preparation of solution for injection 3000 IU ampoules 5 pcs
Longidaza® is used subcutaneously (near the site of the lesion or under scar tissue) or intramuscularly at a dose of 3000 IU in a course of 5 to 25 injections (depending on the disease) with an interval between injections of 3 to 10 days.
Methods of application are selected by the doctor depending on the diagnosis, severity of the disease, clinical course, and age of the patient. If necessary, a repeat course is recommended after 2-3 months.
In the case of treatment of diseases accompanied by a severe chronic productive process in the connective tissue, after a standard course, long-term maintenance therapy with Longidaza® 3000 IU is recommended with breaks between injections of 10-14 days.
To increase the bioavailability of drugs and diagnostic agents, a dose of 1500 IU is recommended with preliminary intramuscular or subcutaneous administration 10-15 minutes into the same place as the main drug.
Dilution: 1. The contents of the ampoule or bottle of Longidaza® 3000 IU are dissolved in 1.0-2.0 ml of procaine solution (0.25% or 0.5%). In case of intolerance to procaine, Longidaza® is dissolved in the same volume of 0.9% sodium chloride solution for injection or water for injection. 2. When used to increase bioavailability, the contents of the ampoule or vial of Longidaza® 3000 IU are dissolved in 2.0 ml, and with a dosage of 1500 IU in 1.0 ml of 0.9% sodium chloride solution for injection. The solvent must be introduced into the bottle or ampoule slowly, wait for 2-3 minutes, and carefully mix without shaking so as not to foam the protein. The prepared solution for parenteral administration cannot be stored. Do not administer intravenously!
Recommended regimens and doses:
For the prevention of adhesive disease and severe scarring after surgical interventions on the abdominal and pelvic organs, intramuscularly at a dosage of 3000 IU once every 3 days for a course of 5 injections. If necessary, the use of Longidaza® can be continued with a total course of up to 10 injections administered once every 5 days.
For treatment.
in gynecology: - adhesions in the pelvis for inflammatory diseases of the internal genital organs, intramuscularly at 3000 IU once every 3-5 days for a course of 10-15 injections; — tubo-peritoneal infertility intramuscularly at 3000 IU in a general course of up to 15 injections: the first 5 injections 1 time in 3 days, then 1 time in 5 days;
in urology: - chronic prostatitis intramuscularly at 3000 IU once every 5 days, a course of 10-15 injections; — interstitial cystitis intramuscularly, 3000 IU once every 5 days, for a course of up to 10 injections;
in surgery: - adhesive disease after surgical interventions on the abdominal organs intramuscularly at a dosage of 3000 IU once every 3-5 days for a course of 10 to 15 injections; - long-term non-healing wounds intramuscularly at a dosage of 3000 IU once every 5 days for a course of 5-10 injections;
in dermatovenereology, cosmetology: - limited scleroderma intramuscularly at 3000-4500 IU once every 3-5 days for a course of up to 20 injections. The dosage and course are selected individually depending on the clinical course, stage, location of the disease and the individual characteristics of the patient; - keloid, hypertrophic and developing scars after pyoderma, burns, operations, injuries: intra-scar or subcutaneous injection near the site of the lesion once every 3 days, for a course of up to 15 injections at a dosage of 3000-4500 IU. The volume of dilution of Longidaza® is selected by the doctor depending on the number of injection points. If necessary, the course can be continued according to the scheme once every 5 days up to 25 injections. Depending on the area of skin damage and the age of scar formation, it is possible to alternate subcutaneous and intramuscular administration once every 5 days at a dosage of 3000 IU, for a course of up to 20 injections.
in pulmonology and phthisiology: - pneumosclerosis intramuscularly at 3000 IU once every 5 days for a course of 10 injections; — fibrosing alveolitis intramuscularly at a dosage of 3000 IU once every 5 days for a course of 15 injections, then maintenance therapy once every 10 days for a total course of up to 25 injections; — tuberculosis intramuscularly at a dosage of 3000 IU once every 5 days for a course of up to 25 injections; depending on the clinical picture and severity of the disease, long-term therapy is possible (from 6 months to 1 year at a dosage of 3000 IU once every 10 days);
in orthopedics: - joint contractures subcutaneously near the lesion site at a dosage of 3000 IU once every 3 days for a course of 5 to 15 injections; - arthrosis, ankylosing spondylitis subcutaneously near the site of the lesion at a dosage of 3000 IU once every 3 days for a course of up to 15 injections; if necessary, treatment can be continued with injections once every 5 days. The duration of maintenance therapy is selected by the doctor depending on the severity of the disease; — hematomas subcutaneously near the site of the lesion at a dosage of 3000 IU once every 3 days for a course of up to 5 injections;
to increase bioavailability: when administered subcutaneously or intramuscularly with diagnostic or medicinal drugs (antibiotics, chemotherapy drugs, anesthetics, etc.). Longidaza® is pre-administered 10-15 minutes in advance at a dosage of 1500 IU in the same way and in the same place as the main drug.
Longidaza
Longidaza® is used subcutaneously (near the site of the lesion or under scar tissue) or intramuscularly at a dose of 3000 IU in a course of 5 to 25 injections (depending on the disease) with an interval between injections of 3 to 10 days.
Methods of application are selected by the doctor depending on the diagnosis, severity of the disease, clinical course, and age of the patient. If necessary, a repeat course is recommended after 2-3 months.
In the case of treatment of diseases accompanied by a severe chronic productive process in the connective tissue, after a standard course, long-term maintenance therapy with Longidaza® 3000 IU is recommended with breaks between injections of 10-14 days.
To increase the bioavailability of drugs and diagnostic agents, a dose of 1500 IU is recommended with preliminary intramuscular or subcutaneous administration 10-15 minutes into the same place as the main drug.
Dilution: 1. The contents of the ampoule or bottle of Longidaza® 3000 IU are dissolved in 1.0-2.0 ml of procaine solution (0.25% or 0.5%). In case of intolerance to procaine, Longidaza® is dissolved in the same volume of 0.9% sodium chloride solution for injection or water for injection. 2. When used to increase bioavailability, the contents of the ampoule or vial of Longidaza® 3000 IU are dissolved in 2.0 ml, and with a dosage of 1500 IU in 1.0 ml of 0.9% sodium chloride solution for injection. The solvent must be introduced into the bottle or ampoule slowly, wait for 2-3 minutes, and carefully mix without shaking so as not to foam the protein. The prepared solution for parenteral administration cannot be stored. Do not administer intravenously!
Recommended regimens and doses:
For the prevention of adhesive disease and severe scarring after surgical interventions on the abdominal and pelvic organs, intramuscularly at a dosage of 3000 IU once every 3 days for a course of 5 injections. If necessary, the use of Longidaza® can be continued with a total course of up to 10 injections administered once every 5 days.
For treatment.
in gynecology: - adhesions in the pelvis for inflammatory diseases of the internal genital organs, intramuscularly at 3000 IU once every 3-5 days for a course of 10-15 injections; — tubo-peritoneal infertility intramuscularly at 3000 IU in a general course of up to 15 injections: the first 5 injections 1 time in 3 days, then 1 time in 5 days;
in urology: - chronic prostatitis intramuscularly at 3000 IU once every 5 days, a course of 10-15 injections; — interstitial cystitis intramuscularly, 3000 IU once every 5 days, for a course of up to 10 injections;
in surgery: - adhesive disease after surgical interventions on the abdominal organs intramuscularly at a dosage of 3000 IU once every 3-5 days for a course of 10 to 15 injections; - long-term non-healing wounds intramuscularly at a dosage of 3000 IU once every 5 days for a course of 5-10 injections;
in dermatovenereology, cosmetology: - limited scleroderma intramuscularly at 3000-4500 IU once every 3-5 days for a course of up to 20 injections. The dosage and course are selected individually depending on the clinical course, stage, location of the disease and the individual characteristics of the patient; - keloid, hypertrophic and developing scars after pyoderma, burns, operations, injuries: intra-scar or subcutaneous injection near the site of the lesion once every 3 days, for a course of up to 15 injections at a dosage of 3000-4500 IU. The volume of dilution of Longidaza® is selected by the doctor depending on the number of injection points. If necessary, the course can be continued according to the scheme once every 5 days up to 25 injections. Depending on the area of skin damage and the age of scar formation, it is possible to alternate subcutaneous and intramuscular administration once every 5 days at a dosage of 3000 IU, for a course of up to 20 injections.
in pulmonology and phthisiology: - pneumosclerosis intramuscularly at 3000 IU once every 5 days for a course of 10 injections; — fibrosing alveolitis intramuscularly at a dosage of 3000 IU once every 5 days for a course of 15 injections, then maintenance therapy once every 10 days for a total course of up to 25 injections; — tuberculosis intramuscularly at a dosage of 3000 IU once every 5 days for a course of up to 25 injections; depending on the clinical picture and severity of the disease, long-term therapy is possible (from 6 months to 1 year at a dosage of 3000 IU once every 10 days);
in orthopedics: - joint contractures subcutaneously near the lesion site at a dosage of 3000 IU once every 3 days for a course of 5 to 15 injections; - arthrosis, ankylosing spondylitis subcutaneously near the site of the lesion at a dosage of 3000 IU once every 3 days for a course of up to 15 injections; if necessary, treatment can be continued with injections once every 5 days. The duration of maintenance therapy is selected by the doctor depending on the severity of the disease; — hematomas subcutaneously near the site of the lesion at a dosage of 3000 IU once every 3 days for a course of up to 5 injections;
to increase bioavailability: when administered subcutaneously or intramuscularly with diagnostic or medicinal drugs (antibiotics, chemotherapy drugs, anesthetics, etc.). Longidaza® is pre-administered 10-15 minutes in advance at a dosage of 1500 IU in the same way and in the same place as the main drug.
